1. From the MTA-SE Momentum Molecular Oncohematology Research Group, 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary
2. Bioinformatics Research Group, Bioinformatics and Sequencing Core Facilities, Szentaágothai Research Centre, University of Peés, Peés, Hungary; Department of Clinical Molecular Biology, Medical University of Bialystok, Białystok, Poland; Medical University of Bialystok, Białystok, Poland
3. Department of Pathology, University of Pécs, Pécs, Hungary
4. Department of Medical Oncology and Haematology, National Institute of Oncology, Budapest, Hungary
5. 1st Department of Internal Medicine, Hematology Division, University of Pécs, Pécs, Hungary
6. Division of Neuropathology, The National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust and Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK
7. NanoString Technologies, Seattle, Washington
8. Incyte Corporation, Wilmington, Delaware
9. Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary
10. Department of Neurooncology, National Institute of Clinical Neurosciences, Budapest, Hungary
11. SE-NAP Brain Metastasis Research Group, Second Department of Pathology, Semmelweis University, Budapest, Hungary